Universal Health Services vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Universal Health Services (UHS) reported ~$15.7B revenue in FY2024. Leading hospital and behavioral health facility operator with 350+ acute care and psychiatric hospitals in the U.S. HQ: King of Prussia, PA.
About
Universal Health Services, Inc. is one of the largest hospital and behavioral health facility operators in the United States, providing acute care hospital services, inpatient and outpatient behavioral health services, and specialized medical services. Founded in 1978 by Alan Miller, UHS operates approximately 350+ facilities — including general hospitals, surgical hospitals, freestanding emergency departments, and over 200 behavioral health centers treating mental illness and substance abuse disorders. The company operates across 37 states, Washington, D.C., and the United Kingdom.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Universal Health Services vs
Bristol Myers Squibb vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.